{"id":"W4212773488","doi":"10.1200/jco.2022.40.6_suppl.224","title":"Randomized phase II trial of neoadjuvant abiraterone plus or minus cabazitaxel in high-risk prostate cancer: ACDC-RP.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University; University of Toronto; London Health Sciences Centre; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Prostate cancer; Cabazitaxel; Internal medicine; Prostatectomy; Randomized controlled trial; Abiraterone acetate; Urology; Prostate; Oncology; Neoadjuvant therapy; Prednisone; Cancer; Androgen deprivation therapy; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002121614,0.002074141,0.002488396,0.0004648899,0.0004529564,0.001357524,0.001001042,0.001875821,0.007827745],"category_scores_gemma":[0.001851786,0.0007289478,0.001190434,0.0004651461,0.001332512,0.0007519739,0.0004604657,0.003282094,0.001535318],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008174171,"about_ca_system_score_gemma":0.002368508,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001233679,"about_ca_topic_score_gemma":0.002879794,"domain_scores_codex":[0.9992394,0.0004571154,0.0000321175,0.0001061576,0.00005855164,0.0001064716],"domain_scores_gemma":[0.9986964,0.0002601934,0.000280649,0.0001409667,0.00009158051,0.0005302591],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9700999,0.01070083,0.0004827664,0.0004428709,0.0004215844,0.00005087486,0.0000387675,0.0004602527,0.002832601,0.0001505149,0.001301122,0.01301778],"study_design_scores_gemma":[0.9608622,0.03770396,0.0003963996,0.00001285863,0.0001019155,0.00003211191,0.000008262007,0.0001958921,0.000178889,0.00007587008,0.0004258799,0.000005771525],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9704343,0.00511199,0.001262387,0.001609812,0.001083986,0.01293378,0.002968206,0.0002955636,0.004299984],"genre_scores_gemma":[0.971607,0.002699143,0.003059451,0.002227257,0.0006272848,0.01074141,0.002784012,0.000041158,0.006213346],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007827745,"threshold_uncertainty_score":0.02618647,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1406137138766023,"score_gpt":0.5090536018849796,"score_spread":0.3684398880083772,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}